4月15日,翰森制药集团有限公司宣布,其自主研发的靶向KRAS G12D小分子1类新药HS-10529片获中国国家药品监督管理局(NMPA)签发的药物临床试验批准通知书,拟开展用于KRAS G12D突变的晚期实体瘤(胰腺癌、结直肠癌、非小细胞肺癌等)的临床。-关于翰森制药-翰森制药集团有限公司成立于2015年12月2日,公司为在中国规模最大、增长最快、临床需求缺口巨大的部分治疗领域均排名前列的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.